Amneal repriced term loans, cutting interest rate margin by 50 basis points

On August 3, 2026, Amneal Pharmaceuticals LLC, a subsidiary of Amneal Pharmaceuticals, Inc., along with certain subsidiary guarantors, entered into Amendment No. 3 to its Term Loan Credit Agreement with JPMorgan Chase Bank, N.A. as administrative agent, with consent from other lenders party to the agreement.¹ The amendment revises terms of the original Term Loan Credit Agreement dated November 14, 2023.¹

Under the amendment, consenting lenders converted their existing term loans on a cashless basis into new term loans totaling $2.039 billion.¹ Separately, the company took on an additional new term loan of $45.2 million, with proceeds used to prepay at par any existing loans that were not converted.¹

The repricing amendment lowers the applicable interest rate margin on the new term loans by 50 basis points, to 1.50% for loans tied to the base rate and 2.50% for loans tied to the secured overnight financing rate.¹ The agreement also permits the company to complete a future repricing transaction without a prepayment premium if it occurs after February 3, 2027.¹ The stated maturity date of August 1, 2032 for the term loans remains unchanged.¹

Amneal said it estimates annualized cash interest expense savings of approximately $12 million from the repricing, based on amounts outstanding under the prior credit agreement immediately before the amendment.¹ The full terms are set out in the Repricing Amendment, attached as Exhibit 10.1 to the filing.¹